File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses

TitleFive-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses
Authors
Issue Date1993
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1993, v. 18 n. 4, p. 763-767 How to Cite?
AbstractIn a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-μg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 mo (group 1), three 5-μg doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 mo (group 2) or three 10-μg doses of plasma-derived hepatitis B vaccine (group 3). The HBs antibody response rate at 8 mo was between 93% and 99%; it was still 75% to 87% at 5 yr in all three groups. Geometric mean titers at 1 yr were 83, 1,085 and 858 mIU/ml in groups 1, 2 and 3, respectively. These values had decreased after 5 yr to 47,131 and 250 mIU/ml. Subjects in group 1 showed a significantly less proportional drop in geometric mean titer at the fifth year than did subjects in group 2 (p = 0.05) or group 3 (p = 0.015). None of the children developed HBc antibody, even after 5 yr of follow-up. We noted 42 episodes of significantly increased HBs antibody titers, probably due to anamnestic response, even when the titers had dropped to low levels. The mean age at which anamnestic response occurred was 8.7 yr. We conclude that (a) the recombinant vaccine and plasma-derived vaccine are comparable in safety and immunogenicity; (b) two doses of vaccine was as effective in protecting hepatitis B infection as three doses, despite lower HBs antibody titers; (c) anamnestic responses occurred most frequently around 4 yr after a child began attending school; and (d) a booster dose was not necessary at 5 yr, probably because of ability of healthy child vaccinees to mount good anamnestic responses.
Persistent Identifierhttp://hdl.handle.net/10722/162016
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorYeoh, EKen_US
dc.contributor.authorLim, WLen_US
dc.contributor.authorChang, WKen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:16:41Z-
dc.date.available2012-09-05T05:16:41Z-
dc.date.issued1993en_US
dc.identifier.citationHepatology, 1993, v. 18 n. 4, p. 763-767en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/162016-
dc.description.abstractIn a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-μg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 mo (group 1), three 5-μg doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 mo (group 2) or three 10-μg doses of plasma-derived hepatitis B vaccine (group 3). The HBs antibody response rate at 8 mo was between 93% and 99%; it was still 75% to 87% at 5 yr in all three groups. Geometric mean titers at 1 yr were 83, 1,085 and 858 mIU/ml in groups 1, 2 and 3, respectively. These values had decreased after 5 yr to 47,131 and 250 mIU/ml. Subjects in group 1 showed a significantly less proportional drop in geometric mean titer at the fifth year than did subjects in group 2 (p = 0.05) or group 3 (p = 0.015). None of the children developed HBc antibody, even after 5 yr of follow-up. We noted 42 episodes of significantly increased HBs antibody titers, probably due to anamnestic response, even when the titers had dropped to low levels. The mean age at which anamnestic response occurred was 8.7 yr. We conclude that (a) the recombinant vaccine and plasma-derived vaccine are comparable in safety and immunogenicity; (b) two doses of vaccine was as effective in protecting hepatitis B infection as three doses, despite lower HBs antibody titers; (c) anamnestic responses occurred most frequently around 4 yr after a child began attending school; and (d) a booster dose was not necessary at 5 yr, probably because of ability of healthy child vaccinees to mount good anamnestic responses.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.titleFive-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responsesen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-0027682677en_US
dc.identifier.volume18en_US
dc.identifier.issue4en_US
dc.identifier.spage763en_US
dc.identifier.epage767en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridYeoh, EK=35427828500en_US
dc.identifier.scopusauthoridLim, WL=36879069900en_US
dc.identifier.scopusauthoridChang, WK=37043471800en_US
dc.identifier.scopusauthoridLin, HJ=37083226800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats